Exco InTouch Announces 1 Million Patients Supported Globally Through its Highly Scalable and Industry Leading Platform
Exco InTouch has announced that one million patients have now benefited from the company’s firmly established and industry leading platform. This significant number underlines the company’s established leadership position in the market and highlights the broad reach of Exco InTouch’s services.
The company’s platform is highly scalable with the proven capability to support cross-border programmes with large patient populations. As a consequence, at any one time hundreds of thousands of patients across multiple territories, time zones and languages benefit from Exco InTouch’s software and services. The geographic spread has so far encompassed patients in a multitude of clinical and healthcare programs across 70 different languages in 26,000 hospitals and clinics across the globe.
Comprehensive regulatory understanding and compliance underlies Exco InTouch’s growth and consistent track record of international success and is an essential attribute for managing clinical and health programs globally. The company is compliant to HIPAA, HITECH, Safe Harbor and international data protection and privacy regulations; thereby marking Exco InTouch out as the most compliant of all the digital patient engagement and data capture solutions providers.
Dale Jessop, Chief Technology Officer at Exco InTouch commented: “The capability to scale-up and to meet head on the challenge of modern clinical and health programmes is the key to success in the complex markets that we serve. To achieve this our platform has been developed to enable delivery of tailored digital and mobile solutions to large numbers of patients, each with different technological needs and expectations, across an array of different regions, languages and cultures.”
He added: “In the fast changing world of digital and mobile technology, the trick is to have the foresight and efficiency to rapidly evolve software and technology with the speed necessary to ensure that effective solutions, that actively engage patients and capture their data, are deployed seamlessly. Furthermore, sufficient investment is of critical importance to provide full confidence that resources are in place to sufficiently guarantee that platforms really are robust enough to meet the demands of servicing such large numbers of patients simultaneously, and on the global scale required, across all the multiple territories concerned.”
Tim Davis, CEO of Exco InTouch commented: “We are of course very pleased that our leading global expertise, knowledge, software and capabilities have been put to use in the servicing of clinical and healthcare programmes on such a scale, enabling the benefits of our advanced offering to be experienced by over a million patients. Indeed, we look forward to many more patients benefiting from our engaging solutions as we continue to expand and develop our advanced capabilities in the industry.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.